PURPOSE OF REVIEW: Paraoxonase-1 (PON1) is an HDL-associated protein of 354 amino acids with a molecular mass of 43 000 Da. It is synthesized in the liver, and in serum it is almost exclusively associated with HDL. PON1 has been reported to be an important contributor to the antioxidant and anti-inflammatory activities of HDL. PON1 impedes oxidative modification of LDL. PON1 serum activity is related to systemic lipid peroxidation stress and prospective cardiovascular risk. In this review, we discuss the relationship between PON1 activity and atherosclerotic diseases and various factors modulating PON1 activity including genes, age, lifestyle factors and medical conditions. Finally, evidence that pharmacological agents may affect PON1 activity is summarized. RECENT FINDINGS: There is increasing evidence from both animal and human studies linking low PON1 activity to an increased likelihood of cardiovascular diseases. Two prospective studies reported a significantly lower incidence of major cardiovascular events in participants with the highest systemic PON1 activity, compared with those with the lowest activity. SUMMARY: PON1 is a potentially antiatherogenic HDL-associated enzyme that protects LDL from oxidative modification. Enhancing PON1 activity could be an important target for future pharmacological agents aimed at decreasing cardiovascular risk.
PURPOSE OF REVIEW: Paraoxonase-1 (PON1) is an HDL-associated protein of 354 amino acids with a molecular mass of 43 000 Da. It is synthesized in the liver, and in serum it is almost exclusively associated with HDL. PON1 has been reported to be an important contributor to the antioxidant and anti-inflammatory activities of HDL. PON1 impedes oxidative modification of LDL. PON1 serum activity is related to systemic lipid peroxidation stress and prospective cardiovascular risk. In this review, we discuss the relationship between PON1 activity and atherosclerotic diseases and various factors modulating PON1 activity including genes, age, lifestyle factors and medical conditions. Finally, evidence that pharmacological agents may affect PON1 activity is summarized. RECENT FINDINGS: There is increasing evidence from both animal and human studies linking low PON1 activity to an increased likelihood of cardiovascular diseases. Two prospective studies reported a significantly lower incidence of major cardiovascular events in participants with the highest systemic PON1 activity, compared with those with the lowest activity. SUMMARY:PON1 is a potentially antiatherogenic HDL-associated enzyme that protects LDL from oxidative modification. Enhancing PON1 activity could be an important target for future pharmacological agents aimed at decreasing cardiovascular risk.
Authors: Andrei Maiseyeu; Hui-Yu Yang; Gajalakshmi Ramanathan; Fen Yin; Robert L Bard; Masako Morishita; J Timothy Dvonch; Lu Wang; Catherine Spino; Bhramar Mukherjee; Marcus A Badgeley; Alma Barajas-Espinosa; Qinghua Sun; Jack Harkema; Sanjay Rajagopalan; Jesus A Araujo; Robert D Brook Journal: Inhal Toxicol Date: 2014-01 Impact factor: 2.724
Authors: Adriaan G Holleboom; Georgios Daniil; Xiaoming Fu; Renliang Zhang; G Kees Hovingh; Alinda W Schimmel; John J P Kastelein; Erik S G Stroes; Joseph L Witztum; Barbara A Hutten; Sotirios Tsimikas; Stanley L Hazen; Angeliki Chroni; Jan Albert Kuivenhoven Journal: Arterioscler Thromb Vasc Biol Date: 2012-09-27 Impact factor: 8.311
Authors: M-H Giroix; J-C Irminger; G Lacraz; C Noll; S Calderari; J A Ehses; J Coulaud; M Cornut; N Kassis; F Schmidlin; J-L Paul; M Kergoat; N Janel; P A Halban; F Homo-Delarche Journal: Diabetologia Date: 2011-07-10 Impact factor: 10.122
Authors: Muhammad Muddasir Qureshi; Warren C McClure; Nicole L Arevalo; Rick E Rabon; Benjamin Mohr; Swapan K Bose; Joe M McCord; Brian S Tseng Journal: J Diet Suppl Date: 2010-06-01